Department of Health and Human ServicesIssuing agency·Maryland·via the SAM.gov Get Opportunities APIWe post new science & technology research opportunities in Maryland as agencies publish them. Get them in one email — free, and unsubscribe whenever.
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes only solicitation; proposals are being requested, and a separate written solicitation will not be issued.
(ii) The solicitation number is 75N98026Q00988. This solicitation is issued as a competitive combined synopsis/solicitation for commercial products or commercial services. The Government intends to award a contract or purchase order resulting from this solicitation using full and open competition.
This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold (if applicable).
The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, seeks to award a (Firm-Fixed-Price) to the offeror responsible whose proposal represents the best value to the Government.
(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular effective August 7, 2026
(iv) The associated NAICS code is 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and the small business size standard is 1000 employees.
This requirement is unrestricted.
The Contractor will conduct a pharmacokinetic (PK) study of the compound (NCGC00592266) in mice following intraperitoneal (IP) administration at 10 mg/kg once daily for 7 consecutive days (QD×7). The study will include collection of plasma, brain, liver, and pancreas samples at the following time points after the final dose: 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, and 24 h (n=3 mice per time point). Drug concentration analysis will be performed in plasma and tissue samples to evaluate systemic and tissue exposure, including potential accumulation following repeated dosing. The Contractor will provide the analytical results and PK data in an Excel report.
"20201""Washington""DC""US""Hubert H. Humphrey Building 200 Independence Avenue, SW ""20892""Bethesda""MD""US""3100 Center Drive Room 1B59""20892""BETHESDA""MD""USA""6011 EXECUTIVE BLVD., SUITE 503L""Sol_75N98026Q00988.pdf"524450"file"".pdf""1""2026-08-07T23:49:55.784+00:00""f36414e9a98847cfa3d549e33ffc0398""public""0""public""7975babc4a1145acbd7eb4561d045b97""0"1"0"Source: SAM.gov (notice cdffe9f5e3a548f28c7074c68de977dc), retrieved via the SAM.gov Get Opportunities API. View the official posting , always confirm requirements and deadlines with the issuing agency.